These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 765264)

  • 1. Mechanisms of natural resistance to trypanosomal infection. Role of complement in avian resistance to Trypanosoma cruzi infection.
    Kierszenbaum F; Ivanyi J; Budzko DB
    Immunology; 1976 Jan; 30(1):1-6. PubMed ID: 765264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-independent, natural resistance of birds to Trypanosoma cruzi infection.
    Kierszenbaum F; Gottlieb CA; Budzko DB
    J Parasitol; 1981 Oct; 67(5):656-60. PubMed ID: 6795329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative resistance of Brazil strain trypomastigote forms of Trypanosoma cruzi to in vitro antibody-dependent complement-mediated lysis.
    Murfin DJ; Kuhn RE
    J Parasitol; 1988 Dec; 74(6):1046-50. PubMed ID: 3057163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis.
    Krettli AU; Weisz-Carrington P; Nussenzweig RS
    Clin Exp Immunol; 1979 Sep; 37(3):416-23. PubMed ID: 116784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease].
    Braun M; de Titto E
    Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.
    Reed SG
    J Immunol; 1988 Jun; 140(12):4342-7. PubMed ID: 3131431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of Trypanosoma cruzi to blood clearance induced by acute-phase immune mouse serum.
    Alvarez JM; Marinho CR; Oshima A; Guimaraes L; Menezes H
    J Parasitol; 1992 Dec; 78(6):1074-7. PubMed ID: 1491301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of cross-reactivity of lytic antibodies with bloodstream forms of Trypanosoma cruzi zymodemes generated in a mouse experimental model.
    Wallace A; Sanchez G; Venegas J; Solari A
    Exp Parasitol; 1995 Mar; 80(2):176-85. PubMed ID: 7895829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between Trypanosoma cruzi and T. rangeli by their different complement sensitivity.
    Schottelius J
    Tropenmed Parasitol; 1982 Sep; 33(3):147-50. PubMed ID: 6814023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: immunological consequences of parasite modification of host cells.
    Ribeiro Dos Santos R; Hudson L
    Clin Exp Immunol; 1980 Apr; 40(1):36-41. PubMed ID: 6771080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of self-cure from Trypanosoma congolense infection in mice.
    Pinder M; Chassin P; Fumoux F
    J Immunol; 1986 Feb; 136(4):1427-34. PubMed ID: 3484768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial characterization of a Trypanosoma cruzi-released decomplementing factor.
    Cunningham DS; Brewer TE; Kuhn RE; Craig WH
    J Parasitol; 1981 Aug; 67(4):475-80. PubMed ID: 6790694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of complement depletion in experimental chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi.
    Budzko DB; Pizzimenti MC; Kierszenbaum F
    Infect Immun; 1975 Jan; 11(1):86-91. PubMed ID: 46840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental Trypanosoma rangeli infection in a murine model.
    Horna AE; Saldaña A; Orn A; Sousa OE
    Rev Biol Trop; 1997 Mar; 44-45():125-9. PubMed ID: 9404516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance against experimental Trypanosoma cruzi infection. Requirements for cellular destruction of circulating forms of T. cruzi in human and murine in vitro systems.
    Kierszenbaum F; Hayes MM
    Immunology; 1980 May; 40(1):61-6. PubMed ID: 6998860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.
    Krettli AU; Brener Z
    J Immunol; 1982 May; 128(5):2009-12. PubMed ID: 6801127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.
    Krettli AU; Pontes de Carvalho LC
    Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies.
    Almeida IC; Milani SR; Gorin PA; Travassos LR
    J Immunol; 1991 Apr; 146(7):2394-400. PubMed ID: 1706399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecific differentiation of Trypanosoma cruzi, Trypanosoma conorhini and Trypanosoma rangeli by lectins in combination with complement lysis.
    Schottelius J; Müller V
    Acta Trop; 1984 Mar; 41(1):29-38. PubMed ID: 6143480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi.
    Cestari Idos S; Krarup A; Sim RB; Inal JM; Ramirez MI
    Mol Immunol; 2009 Dec; 47(2-3):426-37. PubMed ID: 19783051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.